166 related articles for article (PubMed ID: 2127241)
1. Acid beta-glucosidase: enzymology and molecular biology of Gaucher disease.
Grabowski GA; Gatt S; Horowitz M
Crit Rev Biochem Mol Biol; 1990; 25(6):385-414. PubMed ID: 2127241
[TBL] [Abstract][Full Text] [Related]
2. Genetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients.
Grabowski GA; Goldblatt J; Dinur T; Kruse J; Svennerholm L; Gatt S; Desnick RJ
Am J Med Genet; 1985 Jul; 21(3):529-49. PubMed ID: 3927728
[TBL] [Abstract][Full Text] [Related]
3. Gaucher disease: accurate identification of asymptomatic French-Canadian carrier using nonlabeled authentic sphingolipid substrate N-palmitoyl dihydroglucocerebroside.
Choy FY; Bouillon L; Laurin CA
Am J Med Genet; 1987 Aug; 27(4):895-905. PubMed ID: 3425599
[TBL] [Abstract][Full Text] [Related]
4. Intracellular transport of acid beta-glucosidase and lysosome-associated membrane proteins is affected in Gaucher's disease (G202R mutation).
Zimmer KP; le Coutre P; Aerts HM; Harzer K; Fukuda M; O'Brien JS; Naim HY
J Pathol; 1999 Aug; 188(4):407-14. PubMed ID: 10440752
[TBL] [Abstract][Full Text] [Related]
5. Non-neuronopathic Gaucher disease due to saposin C deficiency.
Tylki-Szymańska A; Czartoryska B; Vanier MT; Poorthuis BJ; Groener JA; Ługowska A; Millat G; Vaccaro AM; Jurkiewicz E
Clin Genet; 2007 Dec; 72(6):538-42. PubMed ID: 17919309
[TBL] [Abstract][Full Text] [Related]
6. Mutations causing Gaucher disease.
Horowitz M; Zimran A
Hum Mutat; 1994; 3(1):1-11. PubMed ID: 8118460
[TBL] [Abstract][Full Text] [Related]
7. Acid beta-glucosidase: intrinsic fluorescence and conformational changes induced by phospholipids and saposin C.
Qi X; Grabowski GA
Biochemistry; 1998 Aug; 37(33):11544-54. PubMed ID: 9708990
[TBL] [Abstract][Full Text] [Related]
8. Gaucher disease: a membranous enzymopathy.
Desnick RJ; Grabowski GA; Dinur T; Fabbro D; Goldblatt J; Gatt S
Prog Clin Biol Res; 1982; 97():193-215. PubMed ID: 6818558
[TBL] [Abstract][Full Text] [Related]
9. Use of activators and inhibitors to define the properties of the active site of normal and Gaucher disease lysosomal beta-glucosidase.
Gatt S; Dinur T; Osiecki K; Desnick RJ; Grabowski GA
Enzyme; 1985; 33(2):109-19. PubMed ID: 3924590
[TBL] [Abstract][Full Text] [Related]
10. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations.
Alfonso P; Pampín S; Estrada J; Rodríguez-Rey JC; Giraldo P; Sancho J; Pocoví M
Blood Cells Mol Dis; 2005; 35(2):268-76. PubMed ID: 16039881
[TBL] [Abstract][Full Text] [Related]
11. Combined saposin C and D deficiencies in mice lead to a neuronopathic phenotype, glucosylceramide and alpha-hydroxy ceramide accumulation, and altered prosaposin trafficking.
Sun Y; Witte DP; Zamzow M; Ran H; Quinn B; Matsuda J; Grabowski GA
Hum Mol Genet; 2007 Apr; 16(8):957-71. PubMed ID: 17353235
[TBL] [Abstract][Full Text] [Related]
12. The cytosolic β-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation.
Dekker N; Voorn-Brouwer T; Verhoek M; Wennekes T; Narayan RS; Speijer D; Hollak CE; Overkleeft HS; Boot RG; Aerts JM
Blood Cells Mol Dis; 2011 Jan; 46(1):19-26. PubMed ID: 20728381
[TBL] [Abstract][Full Text] [Related]
13. An evolutionary and structure-based docking model for glucocerebrosidase-saposin C and glucocerebrosidase-substrate interactions - relevance for Gaucher disease.
Atrian S; López-Viñas E; Gómez-Puertas P; Chabás A; Vilageliu L; Grinberg D
Proteins; 2008 Feb; 70(3):882-91. PubMed ID: 17803231
[TBL] [Abstract][Full Text] [Related]
14. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
[TBL] [Abstract][Full Text] [Related]
15. Genetic heterogeneity in type I Gaucher disease.
Devine EA; Beighton P; Petersen EM; Desnick RJ
Prog Clin Biol Res; 1982; 95():495-510. PubMed ID: 6812084
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the gene encoding cytosolic beta-glucosidase in Gaucher disease.
Beutler E; Beutler L; West C
J Lab Clin Med; 2004 Aug; 144(2):65-8. PubMed ID: 15322500
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of type 3 (neuronopathic) Gaucher disease in Thai patients.
Suwannarat P; Keeratichamroen S; Wattanasirichaigoon D; Ngiwsara L; Cairns JR; Svasti J; Visudtibhan A; Pangkanon S
Blood Cells Mol Dis; 2007; 39(3):348-52. PubMed ID: 17689991
[TBL] [Abstract][Full Text] [Related]
18. Posttranslational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts.
Bergmann JE; Grabowski GA
Am J Hum Genet; 1989 May; 44(5):741-50. PubMed ID: 2495719
[TBL] [Abstract][Full Text] [Related]
19. Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease.
Schnabel D; Schröder M; Sandhoff K
FEBS Lett; 1991 Jun; 284(1):57-9. PubMed ID: 2060627
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of Turkish Gaucher disease patients: identification of novel mutations in glucocerebrosidase (GBA) gene.
Emre S; Gürakan F; Yüce A; Rolf A; Scott R; Ozen H
Eur J Med Genet; 2008; 51(4):315-21. PubMed ID: 18586596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
